Search

everythinglearnresearchcommunity

for

Search:↓

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

Microneedling may not significantly enhance hair growth when combined with dutasteride and oral minoxidil, as its primary benefit is improving topical absorption. Some users suggest using a 1.5mm depth for potential follicle stimulation, but results and effectiveness vary.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation is about someone using finasteride and minoxidil along with microneedling as a treatment for hair loss, and there's a mention of scalp tattooing as an alternative or additional approach. Some responses mock the approach, while others inquire about the specifics of the treatment and its effectiveness.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.

Microneedling is debated for hair loss treatment, with some users finding it beneficial for minoxidil absorption and others skeptical of its effectiveness. Alternatives like finasteride and minoxidil are recommended, while tools like dermarollers, dermapens, and dermastamps are discussed for their pros and cons.

Microneedling, comparing dermarollers and dermastamps as treatments for hair loss, and the effectiveness of each. Dermastamps are considered cheaper than dermapens, but users have varying opinions on which method is more effective with less pain.

A user is experimenting with creating a DIY oral Dutasteride solution using raw powder, MCT oil, and Vitamin E to reduce costs. Others discuss their experiences with similar methods and the challenges of sourcing and testing Dutasteride.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

A user shared their hair regrowth success using microneedling with a dermaroller every 6 days and minoxidil, recommending betadine (povidone-iodine) before microneedling to sterilize the scalp and enhance results. Another user noted the potential risks of iodine toxicity.

The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.

A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.

The conversation is about someone experiencing a lot of bleeding from using a 1.0mm microneedling device for hair loss treatment and asking if it's normal. Various users suggest that the bleeding is excessive and recommend using shorter needles or less pressure, while others share their own microneedling practices with different needle lengths and no bleeding.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.

The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.